Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 22, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons regarding the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions rather than a financial performance report.
Material Changes
The material change reported is a transfer of 72,625 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on March 20, 2006, and was advised to the company on March 22, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction is noted as being in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all current and former employees are potential beneficiaries.
Important Facts for Investors
- Transaction Type: Transfer of shares from an employee trust to plan participants.
- Volume: 72,625 Ordinary Shares transferred.
- Directors Involved: Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop are noted as having an interest in the shares held in the GSK Trust in the same capacity as other employees.
- Financial Data: No financial performance data is included in this specific filing.